Interações de Pitolisanto

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (bula de Pitolisanto, Interações medicamentosas)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (bula de Pitolisanto, Interações medicamentosas)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (bula de Pitolisanto, Interações medicamentosas)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (bula de Pitolisanto, Interações medicamentosas)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (bula de Pitolisanto, Interações medicamentosas)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (bula de Pitolisanto, Interações medicamentosas)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (bula de Pitolisanto, Interações medicamentosas)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (bula de Pitolisanto, Interações medicamentosas)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (bula de Pitolisanto, Interações medicamentosas)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (bula de Pitolisanto, Interações medicamentosas)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (bula de Pitolisanto, Interações medicamentosas)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (bula de Pitolisanto, Interações medicamentosas)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (bula de Pitolisanto, Interações medicamentosas)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (bula de Pitolisanto, Interações medicamentosas)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (bula de Entricitabina + rilpivirina + tenofovir, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

Drugs that Prolong the QT Interval : Avoid concomitant use. (bula de Fenobarbital, Interações medicamentosas)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (bula de Pitolisanto, Interações medicamentosas)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

(See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (bula de Foscarnete, Interações medicamentosas)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (bula de Fosfomicina, Interações medicamentosas)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (bula de Pitolisanto, Interações medicamentosas)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (bula de Ivabradina, Advertências e precauções)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (bula de Pitolisanto, Interações medicamentosas)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and with other drugs that prolong the QT interval. (bula de Lopinavir + ritonavir, Advertências e precauções)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (bula de Pitolisanto, Interações medicamentosas)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (bula de Pitolisanto, Interações medicamentosas)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

Examples diazepam, alprazolam, alcohol Drugs that Prolong QTc Interval Clinical Impact The concomitant use of other drugs which prolong the QTc interval with REMERON/REMERONSolTab, increase the risk of QT prolongation and/or ventricular arrhythmias (e.g., Torsades de Pointes). (bula de Mirtazapina, Interações medicamentosas)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (bula de Pitolisanto, Interações medicamentosas)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (bula de Pitolisanto, Interações medicamentosas)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (bula de Oxaliplatina, Interações medicamentosas)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (bula de Pazopanibe, Interações medicamentosas)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

• Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (bula de Propafenona, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

Avoid the concomitant use of drugs known to prolong the QTc interval. (bula de Sertralina, Interações medicamentosas)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (bula de Vepdegestranto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (bula de Arformoterol, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (bula de Buprenorfina, Advertências e precauções)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (bula de Buprenorfina + naloxona, Advertências e precauções)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Carefully monitor cardiac rhythm when administering SUPRANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (bula de Desflurano, Advertências e precauções)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (bula de Eribulina, Advertências e precauções)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

…prolonged QT interval, 3) treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (e.g., diuretics) that may cause electrolyte… (bula de Fentanila, Advertências e precauções)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

…Antidepressants, QTc Prolonging Drugs Formoterol, as with other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (bula de Formoterol, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (bula de Gosserrelina, Advertências e precauções)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

This observation should be considered in making clinical decisions regarding patient monitoring when prescribing HYSINGLA ER in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or who are taking medications that are known to prolong the QTc interval. (bula de Hidrocodona, Advertências e precauções)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Monitor QT interval when administering FORANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (bula de Isoflurano, Advertências e precauções)

TYKERB may prolong the QT interval in some patients. (bula de Lapatinibe, Advertências e precauções)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (bula de Leuprorrelina, Advertências e precauções)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (bula de Lofexidina, Advertências e precauções)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (bula de Mefloquina, Interações medicamentosas)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (bula de Metronidazol, Interações medicamentosas)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (bula de Ponesimode, Interações medicamentosas)

QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between Primaquine phosphate Tablets and other drugs that effect cardiac conduction is unknown. (bula de Primaquina, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (bula de Pitolisanto, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (bula de Rilpivirina, Advertências e precauções)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (bula de Rocurônio, Advertências e precauções)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (bula de Sevoflurano, Advertências)

Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (bula de Subcitrato de bismuto + metronidazol + tetraciclina, Advertências e precauções)

Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (bula de Triptorrelina, Advertências e precauções)

…like other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval or within 2 weeks of discontinuation of such agents, because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (bula de Umeclidínio + vilanterol, Interações medicamentosas)